CD19 and B-cell non-Hodgkin lymphoma: The first large-scale clinical trial of CAR-NK cells (NCT03056339) demonstrated their safety and significant clinical efficacy in patients with CD19+ chronic lymphocytic leukemia and B-cell lymphoma (59).